Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation
about
Mesenchymal Stem Cells: Rising Concerns over Their Application in Treatment of Type One Diabetes MellitusDifferential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell TransplantationMesenchymal Stem Cell Exosomes Induce Proliferation and Migration of Normal and Chronic Wound Fibroblasts, and Enhance Angiogenesis In VitroMesenchymal stromal cell secreted sphingosine 1-phosphate (S1P) exerts a stimulatory effect on skeletal myoblast proliferationPhotoacoustic imaging of mesenchymal stem cells in living mice via silica-coated gold nanorodsMigration and differentiation of human mesenchymal stem cells in the normal rat brain.Influence of immune responses in gene/stem cell therapies for muscular dystrophies.Activation of host tissue trophic factors through JAK-STAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair.Myogenic potential of whole bone marrow mesenchymal stem cells in vitro and in vivo for usage in urinary incontinence.Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repairFetal liver-derived mesenchymal stem cell engraftment after allogeneic in utero transplantation into rabbitsActivation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency.Mesenchymal stem cells can improve anal pressures after anal sphincter injury.Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimenIntramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells.Vascular endothelial growth factor (VEGF) as a key therapeutic trophic factor in bone marrow mesenchymal stem cell-mediated cardiac repairTrophic actions of bone marrow-derived mesenchymal stromal cells for muscle repair/regeneration.Enhancing the efficacy of mesenchymal stem cell therapy.Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.Cell-matrix interactions in muscle disease.Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation.Quantitative proteome profiling of dystrophic dog skeletal muscle reveals a stabilized muscular architecture and protection against oxidative stress after systemic delivery of MuStem cells.The potential of genetically-modified pig mesenchymal stromal cells in xenotransplantationHost tissue response in stem cell therapy.Functional properties of bone marrow derived multipotent mesenchymal stromal cells are altered in heart failure patients, and could be corrected by adjustment of expansion strategies.Histological Evaluation of Experimentally Induced Critical Size Defect Skin Wounds Using Exosomal Solution of Mesenchymal Stem Cells Derived Microvesicles.Human insulin secreted from insulinogenic xenograft restores normoglycemia in type 1 diabetic mice without immunosuppression.
P2860
Q26864580-AEDAE057-BF63-4AC4-8965-07F5E6B7C5E8Q27309883-F2B59B49-CC08-4D61-A944-04CF4AB35F96Q28260373-004DD761-C8E3-417F-AFAF-6106DFF923C1Q28543375-0545DF02-1FFB-4E35-8BE9-0C4A67CB407EQ30457905-6D405285-4466-4164-B049-12A1DD057A2CQ33582855-B0DD6BDC-CA9E-4569-AE2B-8AC514663F95Q33736192-A362EEFA-3EBB-4905-ADDE-8932CD5FCBD7Q34357753-9D264FBB-61AF-4EDC-BEBF-A82B1CE1CE24Q34429321-1B1A0B06-D7E8-4D27-98AA-A42704BBAB2FQ35601392-2CBE4A6E-98BE-4629-B011-6BF5398F7E26Q35673101-28703EEF-9656-4149-BBC8-E090B3929A58Q36382445-986E00EA-5B0A-49BB-AE6B-CA4F08EE045DQ36630100-DCBDF0BC-857C-4CF5-994E-0A62D7A63893Q37276182-C749CFFF-2243-4703-BB33-F5CC82BDA9CBQ37422028-AC126068-3A59-468E-A3D4-6A7D2774D868Q37456840-D844E5F3-8308-446D-A54A-BE258B6F1868Q37512338-F213A692-9A18-4424-BC2B-850726836717Q37723500-75DA4AB9-C49E-46B7-9C54-49CC48EDE1D9Q37802776-0A507AEA-108A-4F57-9F9A-AC82A127C9BDQ37907409-BC767C4D-BF2B-4246-968F-888947F31636Q37944530-C4B17D28-B5F0-4EFA-8DCC-247C15B9FC14Q38043528-5BE9F5D9-5E78-411F-8837-722BFE2EEA5FQ38391853-1FC76269-A8B4-4769-8763-4586F9C71EEFQ39524111-DF394177-99CD-4BE7-AE24-A0C30537CD3CQ41919865-83E6113B-F12E-46FA-8889-8264DE73C92AQ42017721-6CC998BA-9785-441A-B2CC-C7CA92D0879DQ47123474-7D206153-1E52-4FC6-B697-7815C56135D7Q53381073-51828B01-82D9-41C6-8196-94DFE3071BA3
P2860
Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Muscular dystrophy therapy by ...... nosuppression and inflammation
@en
Muscular dystrophy therapy by ...... osuppression and inflammation.
@nl
type
label
Muscular dystrophy therapy by ...... nosuppression and inflammation
@en
Muscular dystrophy therapy by ...... osuppression and inflammation.
@nl
prefLabel
Muscular dystrophy therapy by ...... nosuppression and inflammation
@en
Muscular dystrophy therapy by ...... osuppression and inflammation.
@nl
P2093
P2860
P1433
P1476
Muscular dystrophy therapy by ...... nosuppression and inflammation
@en
P2093
Arsalan Shabbir
Curtis Johnston
David Zisa
Merced Leiker
Techung Lee
P2860
P304
P356
10.1097/TP.0B013E3181A1719B
P577
2009-05-01T00:00:00Z